Chase Science Co., Ltd (SHE:300941)
23.52
+0.04 (0.17%)
At close: Feb 6, 2026
Chase Science Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
| 230.28 | 209.36 | 261.25 | 395.16 | 420.37 | 613.87 | |
Revenue Growth (YoY) | -10.47% | -19.86% | -33.89% | -6.00% | -31.52% | 13.24% |
Cost of Revenue | 133.3 | 103.65 | 118.54 | 218.73 | 246.31 | 382.29 |
Gross Profit | 96.98 | 105.71 | 142.7 | 176.43 | 174.06 | 231.58 |
Selling, General & Admin | 53.3 | 55.25 | 47.12 | 40.55 | 39.36 | 32.86 |
Research & Development | 36.19 | 40.83 | 53.69 | 51.32 | 43.99 | 36.22 |
Other Operating Expenses | 0.4 | -1.32 | -2.93 | -4.71 | -4.96 | -7.18 |
Operating Expenses | 90.96 | 92.5 | 93.3 | 93.92 | 88.4 | 68.44 |
Operating Income | 6.03 | 13.21 | 49.4 | 82.51 | 85.66 | 163.14 |
Interest Expense | -0.23 | -0.23 | -0.23 | -0.26 | -0.22 | - |
Interest & Investment Income | 29.05 | 35.13 | 36.27 | 34.19 | 28.41 | 6.4 |
Currency Exchange Gain (Loss) | 0.03 | 0.03 | 0.03 | 0.14 | -0.04 | -0.11 |
Other Non Operating Income (Expenses) | -0.18 | -0.44 | -0.09 | -0.13 | -0.17 | -0.16 |
EBT Excluding Unusual Items | 34.69 | 47.69 | 85.38 | 116.45 | 113.64 | 169.28 |
Gain (Loss) on Sale of Investments | 0 | 0 | 0.13 | 0.1 | 0.22 | - |
Gain (Loss) on Sale of Assets | 0.07 | 0.06 | -0 | - | -0 | -0.02 |
Asset Writedown | 8.98 | 7.65 | 2.19 | -0 | - | - |
Other Unusual Items | 0.77 | 0.72 | 2.07 | 3.87 | 4.06 | - |
Pretax Income | 44.51 | 56.13 | 89.76 | 120.41 | 117.92 | 169.26 |
Income Tax Expense | 1.81 | 1.01 | 8.06 | 9.91 | 11.89 | 22.9 |
Earnings From Continuing Operations | 42.71 | 55.11 | 81.7 | 110.5 | 106.03 | 146.37 |
Minority Interest in Earnings | -0.07 | 0.49 | -0.43 | 0.02 | - | - |
Net Income | 42.63 | 55.61 | 81.27 | 110.52 | 106.03 | 146.37 |
Net Income to Common | 42.63 | 55.61 | 81.27 | 110.52 | 106.03 | 146.37 |
Net Income Growth | -43.69% | -31.57% | -26.47% | 4.24% | -27.56% | 46.09% |
Shares Outstanding (Basic) | 198 | 206 | 203 | 205 | 204 | 154 |
Shares Outstanding (Diluted) | 198 | 206 | 203 | 205 | 204 | 154 |
Shares Change (YoY) | -3.59% | 1.37% | -0.74% | 0.38% | 32.78% | 0.14% |
EPS (Basic) | 0.22 | 0.27 | 0.40 | 0.54 | 0.52 | 0.95 |
EPS (Diluted) | 0.22 | 0.27 | 0.40 | 0.54 | 0.52 | 0.95 |
EPS Growth | -41.59% | -32.50% | -25.93% | 3.85% | -45.44% | 45.90% |
Free Cash Flow | -100.62 | 14.79 | -2.01 | 88.63 | 101.03 | 154.73 |
Free Cash Flow Per Share | -0.51 | 0.07 | -0.01 | 0.43 | 0.49 | 1.01 |
Dividend Per Share | 0.127 | 0.140 | 0.140 | 0.170 | 0.153 | 0.200 |
Dividend Growth | -20.63% | - | -17.65% | 10.89% | -23.35% | 53.02% |
Gross Margin | 42.12% | 50.49% | 54.62% | 44.65% | 41.41% | 37.72% |
Operating Margin | 2.62% | 6.31% | 18.91% | 20.88% | 20.38% | 26.58% |
Profit Margin | 18.52% | 26.56% | 31.11% | 27.97% | 25.22% | 23.84% |
Free Cash Flow Margin | -43.69% | 7.07% | -0.77% | 22.43% | 24.03% | 25.20% |
EBITDA | 6.41 | 13.71 | 50.07 | 83.18 | 86.47 | 163.97 |
EBITDA Margin | 2.78% | 6.55% | 19.17% | 21.05% | 20.57% | 26.71% |
D&A For EBITDA | 0.38 | 0.51 | 0.67 | 0.67 | 0.82 | 0.82 |
EBIT | 6.03 | 13.21 | 49.4 | 82.51 | 85.66 | 163.14 |
EBIT Margin | 2.62% | 6.31% | 18.91% | 20.88% | 20.38% | 26.58% |
Effective Tax Rate | 4.06% | 1.80% | 8.98% | 8.23% | 10.09% | 13.53% |
Revenue as Reported | 230.28 | 209.36 | 261.25 | 395.16 | 420.37 | 613.87 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.